Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Pricing & Reimbursement

Set Alert for Pricing & Reimbursement

ICER’s Final NASH Report Urges Step Therapy, Specialist Prescribing, Equitable Access

When the first non-alcoholic steatohepatitis drugs reach market, the health cost watchdog says payers will be justified in setting step-therapy including weight-management efforts, while early prescribing should be by specialists.

Cost Effectiveness Drug Review

Chinese Public Payer Data Show More New Drugs Get Faster Coverage

China’s Basic Medical Insurance Fund spent 7.1 times more on novel drugs in 2022 compared to 2019, according to figures disclosed by the National Healthcare Security Administration. Meanwhile, such drugs need to wait less to be eligible for reimbursement in China.

China Reimbursement

CMS Official Calls Medicare Price Negotiations An ‘Ongoing Conversation’

The US Centers for Medicare & Medicaid Services’ Vinod Mitta discussed the agency’s latest thinking on the implementation of Medicare drug price negotiations at the Financial Times Pharma Summit.

Policy Politics

Stock Watch: Orphan Drug Profitability Under Threat

The difficulty of finding and retaining patients with orphan diseases translates into higher marketing costs and adds to other restrictions that limit the attractiveness of some orphan drugs. Will the IRA exacerbate matters?

Stock Watch Rare Diseases

Rinvoq Approved For Crohn’s Disease In Pivotal Year For AbbVie’s Immunology Business

US FDA approval in Crohn’s disease further boosts the revenue potential for Rinvoq as AbbVie navigates a period of declining sales overall due to the introduction of US biosimilars for Humira. 

Approvals Growth

FTC’s Challenge Of Amgen/Horizon Merger Seeks To Fight Pharma Rebating Practices

The US Federal Trade Commission is taking a stand against rebating and bundling practices pharma companies use in negotiations with payers as it seeks to block Amgen’s $28bn acquisition of Horizon.

M & A Pricing Debate

Regeneron CEO Takes Industry Counterview On FTC News: “I’m Glad They’re Looking Into This”

Leonard Schleifer said it is time for US regulators to review whether certain rebate practices are anti-competitive, while speaking at the Financial Times US Pharma & Biotech Summit.

M & A Enforcement

Big Pharma R&D Chiefs On IRA’s Unintended Casualty, Product Life Cycle Compression

R&D heads of Takeda, Amgen, Lilly and Novartis discuss some of the tectonic forces shaping the biopharma sector and the unintended consequences of the IRA on small molecule innovation. Advances in the neurodegenerative diseases segment amid impressive data from donanemab was another key talking point.

Research & Development Pricing Debate

Stock Watch: Queasiness After The Humira Banquet

The second week of first-quarter earnings featured AbbVie’s announcement and a harsh stock price reaction. There were also far-reaching implications behind the results.

Stock Watch Biosimilars

ICER’s NASH Panel Shows Some Enthusiasm For Resmetirom, None For OCA

The cost-effectiveness group voted by a slight margin that Madrigal’s non-alcoholic steatohepatitis drug offers benefit above lifestyle changes alone, but decisively that Intercept’s candidate does not.

Drug Review Reimbursement

BioMarin’s $1m Gene Therapy Roctavian Hits Payer Problems In Germany

BioMarin has yet to treat a patient with Roctavian, the first ever hemophilia A gene therapy, eight months after its first approval in Europe, as pricing delays cloud its commercial prospects.

Commercial Companies

Takeda’s Weber On Digitalizing Pharma In Ongoing Strategic Shift

The entire pharmaceutical industry will transform itself with digital technology while still facing the challenge of financial balance as a part of the healthcare ecosystem, says Takeda's CEO, who shared his views on the firm’s and wider industry's shifting business and R&D strategies at the recent CPHI Japan meeting.

Commercial Digital Health
See All
UsernamePublicRestriction

Register